Arild Nesbakken

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10812157/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: A prospective observational cohort study. Critical Reviews in Oncology/Hematology, 2010, 76, 208-217.	4.4	389
2	Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Lancet, The, 2020, 395, 350-360.	13.7	364
3	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	8.1	227
4	Portrait of the PI3K/AKT pathway in colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1855, 104-121.	7.4	205
5	ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut, 2012, 61, 1560-1567.	12.1	179
6	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.	7.0	177
7	Frailty Is an Independent Predictor of Survival in Older Patients With Colorectal Cancer. Oncologist, 2014, 19, 1268-1275.	3.7	156
8	Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Molecular Cancer, 2011, 10, 85.	19.2	126
9	MiR-9, -31, and -182 Deregulation Promote Proliferation and Tumor Cell Survival in Colon Cancer. Neoplasia, 2012, 14, 868-IN21.	5.3	124
10	ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients. Clinical Cancer Research, 2012, 18, 6001-6010.	7.0	109
11	DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset. PLoS ONE, 2010, 5, e13978.	2.5	102
12	Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. International Journal of Cancer, 2012, 131, 570-581.	5.1	100
13	Frailty indicators and functional status in older patients after colorectal cancer surgery. Journal of Geriatric Oncology, 2014, 5, 26-32.	1.0	84
14	Prognostic Impact of Lymph Node Harvest and Lymph Node Ratio in Patients With Colon Cancer. Diseases of the Colon and Rectum, 2012, 55, 307-315.	1.3	83
15	A comparison of two pre-operative frailty measures in older surgical cancer patients. Journal of Geriatric Oncology, 2012, 3, 1-7.	1.0	80
16	Which elements of a comprehensive geriatric assessment (CGA) predict post-operative complications and early mortality after colorectal cancer surgery?. Journal of Geriatric Oncology, 2010, 1, 57-65.	1.0	79
17	The novel colorectal cancer biomarkers <i>CDO1, ZSCAN18</i> and <i>ZNF331</i> are frequently methylated across gastrointestinal cancers. International Journal of Cancer, 2015, 136, 844-853.	5.1	76
18	Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Molecular Cancer, 2010, 9, 100.	19.2	75

ARILD NESBAKKEN

#	Article	IF	CITATIONS
19	Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Medicine, 2011, 3, 32.	8.2	73
20	Lymph Node Micrometastases and Isolated Tumor Cells Influence Survival in Stage I and II Colon Cancer. Diseases of the Colon and Rectum, 2011, 54, 200-206.	1.3	73
21	Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine, 2017, 9, 46.	8.2	71
22	Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993–2010. Acta Oncológica, 2015, 54, 1714-1722.	1.8	70
23	B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer, 2014, 14, 602.	2.6	69
24	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research, 2020, 26, 4107-4119.	7.0	68
25	Chromatin organisation and cancer prognosis: a pan-cancer study. Lancet Oncology, The, 2018, 19, 356-369.	10.7	67
26	Frailty measures, inflammatory biomarkers and post-operative complications in older surgical patients. Age and Ageing, 2010, 39, 758-761.	1.6	63
27	Prognostic Significance of β-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. Frontiers in Oncology, 2014, 4, 118.	2.8	63
28	Phospholipase C Isozymes Are Deregulated in Colorectal Cancer – Insights Gained from Gene Set Enrichment Analysis of the Transcriptome. PLoS ONE, 2011, 6, e24419.	2.5	58
29	Quality of life in older and frail patients after surgery for colorectal cancer—A follow-up study. Journal of Geriatric Oncology, 2016, 7, 195-200.	1.0	55
30	Establishing Laparoscopic Roux-en-Y Gastric Bypass: Perioperative Outcome and Characteristics of the Learning Curve. Obesity Surgery, 2009, 19, 158-165.	2.1	48
31	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer, 2019, 121, 474-482.	6.4	41
32	CpG island methylator phenotype identifies high risk patients among microsatellite stable <i>BRAF</i> mutated colorectal cancers. International Journal of Cancer, 2017, 141, 967-976.	5.1	40
33	Prognostic, predictive, and pharmacogenomic assessments of <scp>CDX</scp> 2 refine stratification of colorectal cancer. Molecular Oncology, 2018, 12, 1639-1655.	4.6	40
34	Audit of Intraoperative and Early Postoperative Complications after Introduction of Mesorectal Excision for Rectal Cancer. The European Journal of Surgery, 2002, 168, 229-235.	0.9	35
35	Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 3759-3770.	7.0	32
36	A Tissue-Based Comparative Effectiveness Analysis of Biomarkers for Early Detection of Colorectal Tumors. Clinical and Translational Gastroenterology, 2012, 3, e27.	2.5	30

ARILD NESBAKKEN

#	Article	IF	CITATIONS
37	Post-discharge complications in frail older patients after surgery for colorectal cancer. European Journal of Surgical Oncology, 2018, 44, 1542-1547.	1.0	30
38	Common Fusion Transcripts Identified in Colorectal Cancer Cell Lines by High-Throughput RNA Sequencing. Translational Oncology, 2013, 6, 546-IN5.	3.7	29
39	Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. Npj Genomic Medicine, 2021, 6, 59.	3.8	29
40	Sentinel Node Mapping does not Improve Staging of Lymph Node Metastasis in Colonic Cancer. Diseases of the Colon and Rectum, 2008, 51, 891-896.	1.3	27
41	Anticipating the Clinical Use of Prognostic Gene Expression–Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?. Clinical Cancer Research, 2013, 19, 6669-6677.	7.0	27
42	Long-term outcome of palliative treatment with self-expanding metal stents for malignant obstructions of the GI tract. Scandinavian Journal of Gastroenterology, 2012, 47, 1505-1514.	1.5	26
43	High Frequency of Fusion Transcripts Involving TCF7L2 in Colorectal Cancer: Novel Fusion Partner and Splice Variants. PLoS ONE, 2014, 9, e91264.	2.5	26
44	Alternative splicing expands the prognostic impact of <i>KRAS</i> in microsatellite stable primary colorectal cancer. International Journal of Cancer, 2019, 144, 841-847.	5.1	26
45	Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Laboratory Investigation, 2020, 100, 120-134.	3.7	26
46	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine, 2020, 59, 102923.	6.1	22
47	Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian multicenter study. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 3162-3169.	2.4	21
48	The exonâ€level biomarker <i>SLC39A14</i> has organâ€confined cancerâ€specificity in colorectal cancer. International Journal of Cancer, 2012, 131, 1479-1485.	5.1	20
49	Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. Oncogene, 2019, 38, 6109-6122.	5.9	20
50	High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. Clinical Colorectal Cancer, 2020, 19, e26-e47.	2.3	20
51	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis, 2019, 8, 35.	4.9	19
52	A novel transcript, <i>VNN1â€AB</i> , as a biomarker for colorectal cancer. International Journal of Cancer, 2014, 135, 2077-2084.	5.1	18
53	Surgical options and trends in treating rectal prolapse: long-term results in a 19-year follow-up study. Langenbeck's Archives of Surgery, 2018, 403, 991-998.	1.9	17
54	Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clinical Epigenetics, 2018, 10, 70.	4.1	14

ARILD NESBAKKEN

#	Article	IF	CITATIONS
55	Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. European Journal of Surgical Oncology, 2019, 45, 2340-2346.	1.0	14
56	Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. Medical Decision Making, 2015, 35, 255-265.	2.4	12
57	Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Letters, 2020, 469, 246-255.	7.2	12
58	Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a populationâ€based series and a randomized phase III study on adjuvant chemotherapy. Cancer Medicine, 2016, 5, 1840-1849.	2.8	11
59	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open, 2019, 4, e000523.	4.5	11
60	Genomic and prognostic heterogeneity among <i>RAS/BRAF</i> ^{V600E} / <i>TP53</i> coâ€mutated resectable colorectal liver metastases. Molecular Oncology, 2021, 15, 830-845.	4.6	11
61	Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics, 2020, 21, 321-334.	2.8	10
62	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Medicine, 2021, 13, 143.	8.2	10
63	Simultaneous Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: Contemporary Practice, Evidence and Knowledge Gaps. Oncology and Therapy, 2021, 9, 111-120.	2.6	9
64	Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. Modern Pathology, 2022, 35, 1236-1246.	5.5	8
65	Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncológica, 2021, 60, 921-930.	1.8	7
66	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open, 2020, 5, e001040.	4.5	6
67	Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. Journal of Translational Medicine, 2021, 19, 384.	4.4	6
68	The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine, 2021, 13, 142.	8.2	4
69	E adherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular Oncology, 2022, 16, 2312-2329.	4.6	4